Abstract
Elevated urine bis(monoacylglycerol)phosphate (BMP) levels have been found in gain-of-kinase function LRRK2 G2019S mutation carriers. Here, we have expanded urine BMP analysis to other Parkinson’s disease (PD) associated mutations and found them to be consistently elevated in carriers of LRRK2 G2019S and R1441G/C as well as VPS35 D620N mutations. Urine BMP levels are promising biomarkers for patient stratification and potentially target engagement in clinical trials of emerging targeted PD therapies.
Competing Interest Statement
Dr. F Hsieh, Ms. E Tengstrand, and Ms. M Sakalosh are employed by Nextcea, Inc., which holds patent rights to the di-22:6-BMP and 2,2′-di-22:6-BMP biomarkers for neurological diseases involving lysosomal dysfunction (US 8,313,949, Japan 5,702,363, and Europe EP2419742). Dr. K Merchant is a paid advisor to the Michael J Fox Foundation.
Funding Statement
The work was supported by funding from the Michael J. Fox Foundation for Parkinson's Research [MJFF-020316, MJFF-009262]. ES was supported by a Chief Scientist Office Scottish Senior Clinical Academic Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All relevant ethics committees including the Comite etico de investigacion clinica del Area Sanitaria de Gipuzkoa, Donostia Ospitalea, San Sebastian, Spain, the Comite etico de Investigation Clinica del Hospital Clinic de Barcelona, Spain, the ethics committee of the Medical University of Vienna (EK Nr: 1844/2019) and the North East - Newcastle & North Tyneside 2 Research Ethics Committee, United Kingdom (20/YH/0081) gave ethical approval for this work. All participants provided informed written consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Supplemental files updated. Manuscript text revised for clarity.
Data Availability
All data produced in the present work are included in the manuscript as supplementary files.
